基本描述

产品名称	Recombinant Human PLA2G7 Protein
别名	重组人PLA2G7蛋白 \| 重组人脂蛋白关联磷脂酶A2 \| 重组人 PLA2G7 蛋白
英文别名	2-acetyl-1-alkylglycerophosphocholine esterase \| EC 3.1.1 \| EC 3.1.1.47,1-alkyl-2-acetylglycerophosphocholine esterase \| Group-VIIA phospholipase A2 \| gVIIA-PLA2 \| LDL-associated phospholipase A2 \| LDL-PLA(2) \| LDL-PLA2 \| lipoprotein-associated phospholip
规格或纯度	ActiBioPure™, Bioactive, Animal Free, Carrier Free, Azide Free, ≥90%(SDS-PAGE)
产品介绍	Purity >90% (SDS-PAGE) Function Modulates the action of platelet-activating factor (PAF) by hydrolyzing the sn-2 ester bond to yield the biologically inactive lyso-PAF. Has a specificity for substrates with a short residue at the sn-2 position. It is inactive against long-chain phospholipids.
生物活性	Measured by its ability to cleave a colorimetric peptide substrate, 1O-hexadecyl-2-deoxy-2-thio Sacetylsnglyceryl-3-phosphoryl choline (2- Thio-PAF), in the presence of 5, 5’Dithiobis(2-nitrobenzoic acid) (DTNB). The specific activity is >5000 pmoles/min/μg.
内毒素水平	<1.0 EU/μg
表达系统	HEK293
种属	人(Human)
氨基酸	22-441 aa
序列	FDWQYINPVAHMKSSAWVNKIQVLMAAASFGQTKIPRGNGPYSVGCTDLMFDHTNKGTFLRLYYPSQDNDRLDTLWIPNKEYFWGLSKFLGTHWLMGNILRLLFGSMTTPANWNSPLRPGEKYPLVVFSHGLGAFRTLYSAIGIDLASHGFIVAAVEHRDRSASATYYFKDQSAAEIGDKSWLYLRTLKQEEETHIRNEQVRQRAKECSQALSLILDIDHGKPVKNALDLKFDMEQLKDSIDREKIAVIGHSFGGATVIQTLSEDQRFRCGIALDAWMFPLGDEVYSRIPQPLFFINSEYFQYPANIIKMKKCYSPDKERKMITIRGSVHQNFADFTFATGKIIGHMLKLKGDIDSNVAIDLSNKASLAFLQKHLGLHKDFDQWDCLIEGDDENLIPGTNINTTNQHIMLQNSSGIEKYNAHHHHHHHHHH
纯度	＞90% (SDS-PAGE)
蛋白标签	C-His
蛋白长度	Full length protein
无动物源	Yes
Accession #	Q13093
来源	重组表达
预测分子量	49.2 kDa
SDS-PAGE	50-55 kDa, under reducing conditions

储存与运输

应用	Active,SDS-PAGE
物理形态	冻干(Lyophilized)
储存缓冲液	Lyophilized from sterile 50mM NaAc, 150mM NaCl, 10% Glycerol, 5% Trehalose, 5% Mannitol, 0.01% Tween-80, pH5.0
复溶	It is recommended that sterile water be added to the vial to prepare a stock solution of 0.27mg/mL.
储存温度	-20°C储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	收到后在无菌条件下保存，温度为 -20℃ 至 -80℃。收货后建议分装。避免冷冻/解冻循环。
分子类型	蛋白质

图片

Enzyme Activity: Recombinant Human PLA2G7 Protein (rp150291)

Recombinant Human PLA2G7 Protein (rp150291) - Enzyme Activity
Measured by its ability to cleave a colorimetric peptide substrate, 1-O-hexadecyl-2-deoxy-2-thio-S-acetyl-sn-glyceryl-3-phosphorylcholine (2-Thio-PAF) (T334670), in the presence of 5,5’Dithio-bis(2-nitrobenzoic acid) (DTNB) (D425581). The specific activity is >5,000 pmol/min/ug, as measured under the described condition.

SDS-PAGE: Recombinant Human PLA2G7 Protein (rp150291)

Recombinant Human PLA2G7 Protein (rp150291) - SDS-PAGE
3 μg/lane of Recombinant Human PLA2G7 Protein was resolved with SDS-PAGE under reducing (R) and non-reducing (N) conditions and visualized by Coomassie® Blue staining, showing a band at 54.2 kDa.

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到2个结果

批号(Lot Number)	证书类型	货号
ZJ23F0900996	分析证书	rp150291
ZJ23F0900997	分析证书	rp150291

技术文档和文章

阿拉丁®靶点蛋白

Categories: 技术文章

探索主题:

药物开发信号通路细胞因子靶点蛋白药物靶点受体免疫检查点细胞表面标记物

引用文献

1. Wilensky RL, Macphee CH. (2009) Lipoprotein-associated phospholipase A(2) and atherosclerosis.. Curr Opin Lipidol, 20 (5): (415-20). [PMID:19667981]
2. Kruse S, Mao XQ, Heinzmann A, Blattmann S, Roberts MH, Braun S, Gao PS, Forster J, Kuehr J, Hopkin JM et al.. (2000) The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma.. Am J Hum Genet, 66 (5): (1522-30). [PMID:10733466]
3. Tjoelker LW, Wilder C, Eberhardt C, Stafforini DM, Dietsch G, Schimpf B, Hooper S, Le Trong H, Cousens LS, Zimmerman GA et al.. (1995) Anti-inflammatory properties of a platelet-activating factor acetylhydrolase.. Nature, 374 (6522): (549-53). [PMID:7700381]
4. Woolford AJ, Day PJ, Bénéton V, Berdini V, Coyle JE, Dudit Y, Grondin P, Huet P, Lee LY, Manas ES et al.. (2016) Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2).. J Med Chem, 59 (23): (10738-10749). [PMID:27933945]
5. Liu Q, Huang F, Yuan X, Wang K, Zou Y, Shen J, Xu Y. (2017) Structure-Guided Discovery of Novel, Potent, and Orally Bioavailable Inhibitors of Lipoprotein-Associated Phospholipase A2.. J Med Chem, 60 (24): (10231-10244). [PMID:29193967]
6. Hoover HS, Blankman JL, Niessen S, Cravatt BF. (2008) Selectivity of inhibitors of endocannabinoid biosynthesis evaluated by activity-based protein profiling.. Bioorg Med Chem Lett, 18 (22): (5838-41). [PMID:18657971]
7. Diana M Stafforini,James R Sheller,Timothy S Blackwell,Adam Sapirstein,Fiona E Yull,Thomas M McIntyre,Joseph V Bonventre,Stephen M Prescott,L Jackson Roberts. (2005-12-24) Release of free F2-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasma platelet-activating factor acetylhydrolases.. The Journal of biological chemistry, 281 ((8)): (4616-4623). [PMID:16371369]
8. Xinde Chen,Wenwei Xu,Kai Wang,Mingguang Mo,Wei Zhang,Lili Du,Xiaojing Yuan,Yechun Xu,Yiping Wang,Jianhua Shen. (2015-10-20) Discovery of a Novel Series of Imidazo[1,2-a]pyrimidine Derivatives as Potent and Orally Bioavailable Lipoprotein-Associated Phospholipase A2 Inhibitors.. Journal of medicinal chemistry, 58 ((21)): (8529-8541). [PMID:26479945]
9. Chen X, Wang K, Xu W, Ma Q, Chen M, Du L, Mo M, Wang Y, Shen J.. (2016) Discovery of Potent and Orally Active Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors as a Potential Therapy for Diabetic Macular Edema.. J Med Chem, 59 (6): (2674-2687). [PMID:26927682] [10.1021/acs.jmedchem.5b01930]
10. Woolford AJ, Pero JE, Aravapalli S, Berdini V, Coyle JE, Day PJ, Dodson AM, Grondin P, Holding FP, Lee LY, Li P, Manas ES, Marino J, Martin AC, McCleland BW, McMenamin RL, Murray CW, Neipp CE, Page LW, Patel VK, Potvain F, Rich S, Rivero RA, Smith K, Somers DO, Trottet L, Velagaleti R, Williams G, Xie R.. (2016) Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Discovered through X-ray Fragment Screening.. J Med Chem, 59 (11): (5356-5367). [PMID:27167608] [10.1021/acs.jmedchem.6b00212]
11. Liu Q, Chen X, Chen W, Yuan X, Su H, Shen J, Xu Y.. (2016) Structural and Thermodynamic Characterization of Protein-Ligand Interactions Formed between Lipoprotein-Associated Phospholipase A2 and Inhibitors.. J Med Chem, 59 (10): (5115-5120). [PMID:27078579] [10.1021/acs.jmedchem.6b00282]
12. Tjoelker, L W LW and 8 more authors.. (1995) Plasma platelet-activating factor acetylhydrolase is a secreted phospholipase A2 with a catalytic triad.. The Journal of biological chemistry, (27): [PMID:7592717]
13. Tew, D G DG and 8 more authors.. (1996) Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins.. Arteriosclerosis, thrombosis, and vascular biology, [PMID:8624782]
14. Stafforini, D M DM and 11 more authors.. (1996) Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase.. The Journal of clinical investigation, (15): [PMID:8675689]
15. Yamada, Y Y and Yokota, M M.. (1997) Loss of activity of plasma platelet-activating factor acetylhydrolase due to a novel Gln281-->Arg mutation.. Biochemical and biophysical research communications, (30): [PMID:9245731]
16. Hiramoto, M M, Yoshida, H H, Imaizumi, T T, Yoshimizu, N N and Satoh, K K.. (1997) A mutation in plasma platelet-activating factor acetylhydrolase (Val279-->Phe) is a genetic risk factor for stroke.. Stroke, [PMID:9412624]
17. Yamada, Y Y, Ichihara, S S, Fujimura, T T and Yokota, M M.. (1998) Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men.. Metabolism: clinical and experimental, [PMID:9472966]
18. Yoshida, H H and 7 more authors.. (1998) A mutation in plasma platelet-activating factor acetylhydrolase (Val279Phe) is a genetic risk factor for cerebral hemorrhage but not for hypertension.. Thrombosis and haemostasis, [PMID:9759612]
19. Kriska, Tamas T, Marathe, Gopal K GK, Schmidt, Jacob C JC, McIntyre, Thomas M TM and Girotti, Albert W AW.. (2007) Phospholipase action of platelet-activating factor acetylhydrolase, but not paraoxonase-1, on long fatty acyl chain phospholipid hydroperoxides.. The Journal of biological chemistry, (5): [PMID:17090529]
20. Gardner, Alison A AA, Reichert, Ethan C EC, Topham, Matthew K MK and Stafforini, Diana M DM.. (2008) Identification of a domain that mediates association of platelet-activating factor acetylhydrolase with high density lipoprotein.. The Journal of biological chemistry, (20): [PMID:18434304]
21. Samanta, Uttamkumar U and Bahnson, Brian J BJ.. (2008) Crystal structure of human plasma platelet-activating factor acetylhydrolase: structural implication to lipoprotein binding and catalysis.. The Journal of biological chemistry, (14): [PMID:18784071]
22. Samanta, Uttamkumar; Kirby, Stephen D; Srinivasan, Prabhavathi; Cerasoli, Douglas M and Bahnson, Brian J.. (2009) Crystal structures of human group-VIIA phospholipase A2 inhibited by organophosphorus nerve agents exhibit non-aged complexes.. Biochemical pharmacology, (15): [PMID:19394314]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

=

浓度

x

体积

x

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

x

体积 1 (V1)

=

浓度 2 (C2)

x

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

=

质量（小瓶）

÷

所需的复溶浓度

货号 (SKU)	包装规格	是否现货
rp150291-10μg	10μg	现货
rp150291-20μg	20μg	期货
rp150291-50μg	50μg	现货
rp150291-100μg	100μg	期货
rp150291-1mg	1mg	期货

Recombinant Human PLA2G7 Protein

库存信息

库存信息

库存信息

库存信息

库存信息

基本描述

储存与运输

图片

质检证书（CoA,COO,BSE/TSE 和分析图谱)

技术文档和文章

引用文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器